Advertisement
Australia markets closed

  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     

  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     

  • AUD/USD

    0.6672
    -0.0009 (-0.13%)
     

  • OIL

    79.61
    +0.38 (+0.48%)
     

  • GOLD

    2,389.50
    +4.00 (+0.17%)
     

  • Bitcoin AUD

    98,683.70
    -205.48 (-0.21%)
     

  • CMC Crypto 200

    1,379.46
    +5.61 (+0.41%)
     

  • AUD/EUR

    0.6141
    +0.0002 (+0.03%)
     

  • AUD/NZD

    1.0898
    -0.0008 (-0.07%)
     

  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     

  • NASDAQ

    18,557.96
    -38.69 (-0.21%)
     

  • FTSE

    8,438.65
    -7.15 (-0.08%)
     

  • Dow Jones

    39,869.38
    -38.62 (-0.10%)
     

  • DAX

    18,738.81
    -130.55 (-0.69%)
     

  • Hang Seng

    19,465.85
    +89.32 (+0.46%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024

Business Wire
·1-min read

SAN FRANCISCO, April 30, 2024--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430254007/en/

Contacts

Media
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1 314-368-5189

Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
+1 978-973-9986